SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as the market keenly anticipates a pivotal Department of Energy announcement regarding surplus plutonium awards, a key catalyst for its advanced nuclear technology. Bullish sentiment is driven by expectations of government support and institutional accumulation during a perceived oversold period. Conversely, bears emphasize substantial insider selling and ongoing share dilution, raising concerns about the company's valuation given its current lack of commercial revenue.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

EKSO is experiencing significant upward momentum and trading volume following the announcement of a proposed business combination with Applied Digital's cloud division, forming a new AI compute platform, ChronoScale. The community is actively discussing this pivot into AI infrastructure, with many anticipating a substantial short squeeze despite lingering concerns about potential dilution. This move highlights EKSO's transformation into a key player in the rapidly expanding AI sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing significant volatility and trending amid intense community debate. A recent sharp rebound from declines, attributed by many to alleged manipulation via margin calls, is fueling discussion of a potential short squeeze. The market is buzzing with anticipation over imminent silver export restrictions from China, effective January 1st, 2026, which bulls believe will profoundly impact supply and drive prices higher due to rising industrial demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending fueled by its highly engaged community, passionately advocating for the "OG meme" narrative of Rage Comics and actively building out an ecosystem with tools like RageMaker and RageGames. This dedicated base expresses strong conviction, viewing RAGE as significantly undervalued and poised for substantial long-term growth as they lead a "return to the memes" within the broader market upswing.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to significant community debate and anticipation surrounding potential positive announcements at the upcoming CES 2026. While many investors express frustration over recent price declines, a bullish contingent highlights analyst upgrades, institutional buying, and the company's strong fundamentals in agentic AI voice solutions for automotive and restaurant sectors, viewing current levels as a strategic buying opportunity for long-term growth.

BUUU Group Ltd. is a holding company, which operates through its subsidiaries, BU Creation and BU Workshop. Its subsidiaries engage in design, planning and production of face-to-face events, immersive environments and brand-based experiences for clients and venues, including event organizers, consumer brand marketers and retail shopping centers. The company was founded in 2017 and is headquartered in Hong Kong.

BUUU Group Ltd. - Ordinary Shares - Class A

BUUU Group Ltd

BUUU Group Ltd is experiencing extreme volatility and intense speculative trading, driven by comparisons to other high-flying, low-float Chinese stocks. While many traders are actively chasing rapid gains, a significant portion of the community warns of a potential pump and dump scenario, fueling a highly divided discussion.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending following positive Phase 3 trial data for its relacorilant candidate in platinum-resistant ovarian cancer, sparking community debate over market valuation and intense short-seller activity. Investors are also focused on an upcoming regulatory decision for relacorilant in Cushing's syndrome and promising survival data from its ALS program, fueling discussions about the company's long-term growth and potential for a significant short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending with high anticipation for multiple imminent FDA decisions, including a PDUFA date for its motion sickness drug, Tradipitant, and an expedited re-review for Hetlioz in jet lag. The community is actively discussing Tradipitant's significant potential in addressing GLP-1 induced nausea, viewing these regulatory catalysts as crucial for a re-rating given the company's improved relationship with the FDA. Investors are keenly watching for outcomes that could lead to considerable stock movement, drawing comparisons to other recent biotech approvals.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending on expectations of a significant refinancing wave and broader housing market recovery as monetary policy is anticipated to ease, positioning its integrated mortgage and fintech platform for growth. Community discussions highlight the company's strong technical setup, strategic advantages from its full ecosystem including Mr. Cooper and Redfin, and the potential for increased operating leverage through AI-driven efficiency. While many foresee substantial upside from cycle normalization, some caution against expecting a repeat of past rapid price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Pharmaceutical Stocks To Add to Your Watchlist - December 30th

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, Abbott Laboratories, and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical...

BMY vs AMGN: Which Biotech Stock Is More Resilient Now?

AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

<p>Hunterbrook Capital on Tuesday revealed it is long on Achieve Life Sciences (ACHV) stock as the company nears a green light from the U.S. Food and Drug Administration for Cytisinicline as a treatment for smoking addiction.</p><p>The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. If approved, the company plans to sell it in the U.S. by the end of the year.</p><p>Hunterbrook Media <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://hntrbrk.com/achieve/">said</a> that Cytisinicline is already used in Europe and added that smoking cessation clinicians, scientists, and health program directors that it interviewed recommended approval in the U.S.</p><p>The report also noted that Cytisinicline has proven safer and more effective than its predecessors including Pfizer’s Chantix and GlaxoSmithKline’s Zyban. Chantix, despite side effects, earned over $1 billion in peak annual sales and it, like GSK’s Zyban, also required longer treatment than Cytisinicline, the firm said.</p><p>Furthermore, despite smoking being on the decline, it is still rampant, the firm noted.</p><p>There are about 29 million American cigarette smokers and about 28 million e-cigarette users, including many middle and high schoolers, the firm said. While about a half of this population try to quit, only a small portion succeeds.</p><h2 class="st-heading-2">FDA Priority Review Voucher</h2><p>The FDA awarded Achieve a Commissioner's National Priority Voucher (CNPV) aimed at expediting review for Cytisinicline in October. “It's been nearly two decades since a new treatment option for smoking cessation was approved, and there are currently no treatment options for vaping cessation,” Achieve CEO Rick Stewart said then.</p><h2 class="st-heading-2">Hunterbrook Flags Potential Headwinds</h2><p>“As with all applications, the FDA could still require additional data or studies if any safety concerns arise. Achieve also needs to maintain long-term access to cytisinicline supply. &nbsp;The company is in a legal dispute with its original supplier, Sopharma, though Achieve named other suppliers in its FDA application,” Hunterbrook said.</p><p>The firm also flagged funding concerns, highlighting that while Achieve is funded through the second quarter of 2026, it will need to raise more capital to commercialize the drug after receiving approval.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>ACHV stock traded 7% higher at the time of writing. On Stocktwits, retail sentiment around ACHV jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.</p><p><a href="https://stocktwits.com/symbol/ACHV">ACHV stock</a> has gained 34% this year and by about 31% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/walmart-app-website-down-for-users-amid-new-year-shopping-rush/cL7I4vlREyI">Walmart App And Website Down For Users Amid New Year Shopping Rush</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, the Achieve Life Sciences logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook

The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026.

Equity

Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.2% during the third quarter, according to its most recent disclosure with...

Mattson Financial Services LLC Has $665,000 Stock Position in Pfizer Inc. $PFE

Mattson Financial Services LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 62.9% in the 3rd quarter, according to the company in its most recent filing with the...

Top Dividend Stocks To Follow Today - December 29th

Direxion Daily TSLA Bull 2X Shares, Exxon Mobil, and Pfizer are the three Dividend stocks to watch today, according to MarketBeat's stock screener tool. Dividend stocks are shares of companies that...

Top Pharmaceutical Stocks To Research - December 29th

Eli Lilly and Company, Novo Nordisk A/S, Pfizer, Ultragenyx Pharmaceutical, Praxis Precision Medicines, AbbVie, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according...

Top Medical Stocks To Add to Your Watchlist - December 29th

Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, Pfizer, Johnson & Johnson, Merck & Co., Inc., and Ultragenyx Pharmaceutical are the seven Medical stocks to watch today, according to...

Live Oak Private Wealth LLC Has $449,000 Stake in Pfizer Inc. $PFE

Live Oak Private Wealth LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 92.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the...

Top Pharmaceutical Stocks To Follow Now - December 28th

Eli Lilly and Company, Novo Nordisk A/S, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of...

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PFE News

PFEPfizer Inc